About
Electra Therapeutics, Inc.
Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer.
Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professionals to find an approved treatment for secondary hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory condition.
Electra Therapeutics, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:ETRA
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Profitability & Returns
Margins and return on capital
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-09-29 | $11.21 | $11.94 | $11.00 | $11.35 | $11.35 | +0.14 | 715,600 |
| 2026-09-28 | $11.52 | $11.91 | $11.14 | $11.32 | $11.32 | -0.20 | 537,100 |
| 2026-09-25 | $11.70 | $12.75 | $11.27 | $11.55 | $11.55 | -0.15 | 438,400 |
| 2026-09-24 | $12.54 | $13.56 | $11.71 | $11.82 | $11.82 | -0.72 | 445,200 |
| 2026-09-23 | $13.56 | $14.18 | $12.50 | $12.67 | $12.67 | -0.89 | 875,400 |
| 2026-09-22 | $13.88 | $14.12 | $13.11 | $13.62 | $13.62 | -0.26 | 439,700 |
| 2026-09-21 | $13.94 | $14.48 | $13.48 | $13.92 | $13.92 | -0.02 | 813,200 |
| 2026-09-18 | $15.00 | $15.50 | $13.25 | $13.25 | $13.25 | -1.75 | 5,124,300 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13G | Sep 28, 2026 | Filing |
| SCHEDULE 13G | Sep 28, 2026 | Filing |
| SCHEDULE 13D | Sep 25, 2026 | Filing |
| S-8 | Sep 21, 2026 | Securities to be offered to employees in employee benefit plans |
| 8-K | Sep 21, 2026 | Current Report |
| 424B4 | Sep 18, 2026 | Prospectus |
| CERT | Sep 18, 2026 | Certification by an exchange approving securities for listing |
| 8-A12B | Sep 18, 2026 | Registration of securities |
| EFFECT | Sep 17, 2026 | Notice of Effectiveness |
| S-1MEF | Sep 17, 2026 | Registration adding securities to prior Form S-1 registration |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Quehuong (Kathy) Dong, Pharm.D., M.B.A.
President, Chief Executive Officer, Director
Chris Clark, C.F.A.
Chief Financial Officer
Kim-Hien Dao, D.O., Ph.D.
Chief Medical Officer
Gary S. Koe, Ph.D.
Chief Technical Officer
Graham Parry, Ph.D.
Chief Scientific Officer
Nancy Stagliano, Ph.D.
Chairperson
Matthew Fust, M.B.A.
Director
Thomas Geninatti, Ph.D.
Director
Carl L. Gordon, Ph.D., C.F.A.
Director
Beth Seidenberg, M.D.
Director
